Latin America Antibody Drug Conjugates Market Size & Outlook
Related Markets
Latin America antibody drug conjugates market highlights
- The Latin America antibody drug conjugates market generated a revenue of USD 107.2 million in 2021.
- The market is expected to grow at a CAGR of 21.5% from 2022 to 2030.
- In terms of segment, blood cancer was the largest revenue generating application in 2021.
- Blood Cancer is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, Mexico is expected to register the highest CAGR from 2022 to 2030.
Latin America data book summary
| Market revenue in 2021 | USD 107.2 million |
| Market revenue in 2030 | USD 617.0 million |
| Growth rate | 21.5% (CAGR from 2021 to 2030) |
| Largest segment | Blood cancer |
| Fastest growing segment | Blood Cancer |
| Historical data covered | 2018 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Breast Cancer |
| Key market players worldwide | Pfizer Inc, Takeda Pharmaceutical Co Ltd, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc, Daiichi Sankyo Co Ltd, GlaxoSmithKline Consumer Healthcare (GSK CH India), Astellas Pharma Inc, ADC Therapeutics SA |
Other key industry trends
- In terms of revenue, Latin America region accounted for 1.8% of the global antibody drug conjugates market in 2021.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- MEA is the fastest growing regional market and is projected to reach USD 396.2 million by 2030.
Blood cancer was the largest segment with a revenue share of 54.85% in 2021. Horizon Databook has segmented the Latin America antibody drug conjugates market based on blood cancer, breast cancer covering the revenue growth of each sub-segment from 2018 to 2030.
Latin America’s market is characterized by a growing cancer patient population due to a combination of demographic, environmental, and socioeconomic problems. The level of cancer care provided differs across countries based on the level of public funding for healthcare.
Individuals living in countries such as Brazil, which provides free public health services, have wider access to ADC drugs due to them being covered under the public healthcare system. Other countries such as Mexico and Argentina have approved ADC drugs.
However, a wide-scale benefit is not delivered due to larger populations, lack of adequate planning for cancer at the national level, regional differences in the levels of care, and unequal coverage across different insurance providers.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antibody Drug Conjugates Market Scope
Antibody Drug Conjugates Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Latin America antibody drug conjugates market size, by country, 2018-2030 (US$M)
Latin America Antibody Drug Conjugates Market Outlook Share, 2021 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
